This inventor holds 2 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 1 EPO patent. Top assignee: Eisai R&d Management Co., Ltd.. Active years: 2017-2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017-2018
Title: Shunsuke Ozaki: Innovator in Pharmaceutical Chemistry
Introduction
Shunsuke Ozaki is a notable inventor based in Kamisu, Japan. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 2 patents. His work focuses on developing innovative compounds that have potential applications in drug formulation.
Latest Patents
Ozaki's latest patents include the "Salt of monocyclic pyridine derivative and crystal thereof." This invention provides salts consisting of an organocarboxylic acid, such as succinic acid and maleic acid, combined with a specific compound. These salts and their crystals can be utilized as bulk materials for pharmaceuticals. Another significant patent is the "Salt of pyrazoloquinoline derivative, and crystal thereof." This invention details a salt of a specific pyrazoloquinoline compound and various acids, which may serve as a drug substance in pharmaceuticals.
Career Highlights
Shunsuke Ozaki is currently associated with Eisai R&D Management Co., Ltd., where he continues to advance his research in pharmaceutical innovations. His work is characterized by a commitment to enhancing drug development processes and improving therapeutic outcomes.
Collaborations
Ozaki collaborates with esteemed colleagues, including Kenshi Yoshida, to further his research endeavors. Their combined expertise contributes to the innovative projects at Eisai R&D Management Co., Ltd.
Conclusion
Shunsuke Ozaki's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for advancements in drug development and therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
